Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences

A considerable degree of overlap exists between reimbursement and regulatory approval of health technologies, and harmonization of certain aspects is both possible and feasible. Various models to harmonization have been suggested in which a number of practical attempts have been drawn from. Based on a review of the literature, approaches can be categorized into those focused on reducing uncertainty and developing economies of scale in the evidentiary requirements; and/or aligning timeframes and logistical aspects of the review process. These strategies can further be classified based on the expected level of structural and organizational change required to implement them into the existing processes. Passive processes require less modification, whereas active processes are associated with greater restructuring. Attempts so far at harmonization have raised numerous legal and practical issues and these must be considered when introducing a more harmonized framework into the existing regulatory and reimbursement arrangements.

[1]  Ruth Ellen Bulger,et al.  The Institute of Medicine , 1992, JAMA.

[2]  P. Villeneuve The Placebo Standard in Regulatory Market Approval: Why the Declaration of Helsinki Has Been Ignored for 35 years , 2020 .

[3]  Doug Coyle,et al.  The Potential Impact Of Recommendations Made Through The Common Drug Review Program At The Canadian Agency For Drugs And Technologies In Health , 2014 .

[4]  I. Wiklund,et al.  Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research. , 2012, Drug discovery today.

[5]  J. Belsey,et al.  Addressing the health technology assessment of biosimilar pharmaceuticals , 2010, Current medical research and opinion.

[6]  K. Tolley Pharmaceutical market access and the challenges of health technology assessment in the United Kingdom , 2010 .

[7]  R. Barker A flexible blueprint for the future of drug development , 2010, The Lancet.

[8]  Michael Drummond,et al.  Economic evaluation for devices and drugs--same or different? , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  Marc L. Berger,et al.  Comparative Effectiveness Research , 2012, PharmacoEconomics.

[10]  J. Hutton,et al.  The feasibility of harmonizing health technology assessments across jurisdictions: A case study of drug eluting stents , 2009, International Journal of Technology Assessment in Health Care.

[11]  Malcolm Rowland,et al.  Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response , 2011, Nature Reviews Drug Discovery.

[12]  Martin McKee,et al.  Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union , 2008 .

[13]  F. Pichler,et al.  INTERACTION INITIATIVES BETWEEN REGULATORY, HEALTH TECHNOLOGY ASSESSMENT AND COVERAGE BODIES, AND INDUSTRY , 2012, International Journal of Technology Assessment in Health Care.

[14]  R. Epstein,et al.  Integrating new approaches for clinical development: translational research and relative effectiveness. , 2012, Journal of comparative effectiveness research.

[15]  M. Drummond,et al.  Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  Rebecca S. Graves,et al.  Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. , 2002 .

[17]  S. Walker,et al.  Preparing for Regulatory Review and Reimbursement Decisions , 2009, Pharmaceutical Medicine.

[18]  J. Abraham The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .

[19]  Katrine Frønsdal,et al.  Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities , 2011, International Journal of Technology Assessment in Health Care.

[20]  J. Iglehart,et al.  Centers for Medicare and Medicaid Services , 2020, Definitions.

[21]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[22]  H. Eichler,et al.  Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval , 2012, Clinical pharmacology and therapeutics.

[23]  Steven Pearson,et al.  Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers , 2010, Nature Reviews Drug Discovery.